Skip to main content

Table 3 Summary of studies of dry powder measles product presented to the expert group for stage II of the CHNRI process

From: An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children

Reference Factor for investigation Results Conclusions
LiCalsi, C., et al
Feasibility of dry powder inhalation in measles Optimal vaccine delivery site – lungs; Particle sizing 1-5μm; Preparation – micronization and jet-milling ;3 Spiros delivery devices designed Undemonstrable clinical application
de Swart, R.L., et al
Dry powder vaccination in Macaques Low seroresponse to measles dry powder blend compared to injection or liquid aerosol vaccination Proof of principle evident by stimulation of weak immune response. Poor device design in macaque model – loss of vaccine at delivery.
LiCalsi, C., et al
Dry powder measles vaccine potency retention Up to 89% viral potency retention can be achieved with micronization.  
Burger, J.L., et al
Stabilizing dry powder measles formulations Myo-inositol> trehalose as a sugar stabilizer in dry powder measles vaccinations Myo-inositol is relatively unhygroscopic, improving its dry powder vaccination credentials